
April 4 (Reuters) - Johnson & Johnson JNJ.N:
TREMFYA® (GUSELKUMAB) IS THE FIRST AND ONLY IL-23 INHIBITOR TO SIGNIFICANTLY REDUCE BOTH THE SIGNS AND SYMPTOMS AND THE PROGRESSION OF STRUCTURAL DAMAGE IN ADULTS LIVING WITH ACTIVE PSORIATIC ARTHRITIS
JOHNSON & JOHNSON - TREMFYA PHASE 3B STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS
JOHNSON & JOHNSON - TREMFYA SAFETY PROFILE CONSISTENT WITH NO NEW SAFETY SIGNALS
JOHNSON & JOHNSON - TREMFYA SHOWS LESS STRUCTURAL DAMAGE PROGRESSION AT WEEK 24